Victoria, British Columbia, Canada, June 19, 2018 - IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has closed its previously announced non-brokered private placement financing by issuing a total of 875,000 units (“Units”) of ImmunoPrecise at a price of $0.80 per Unit for gross proceeds of $700,000 (the “Financing”).   … Continue reading